Comments
Sun Pharmaceutical Industries’ subsidiary has received approval from the US health regulator for YONSA, used for the treatment of a form of prostate cancer.
In a regulatory filing, Sun Pharma and Churchill Pharmaceuticals, LLC said: “One of Sun Pharma’s wholly owned subsidiary companies has received approval from the US Food and Drug Administration (USFDA) for YONSA.”
YONSA (abiraterone acetate) in combination with methylprednisolone is a novel formulation for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the company said.
Sun Pharma said Churchill is eligible to receive upfront and sales-linked milestone payments as well as royalties on sales pursuant to an agreement between the two companies to commercialise YONSA in the US.
YONSA in combination with methylprednisolone has been filed as a new drug application (NDA) and will be promoted as a branded product in the US, Sun Pharma added.
Shares of Sun Pharma were trading 1.49 per cent higher at Rs 459.75 apiece on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.